5-Methyl-1,3,4-thiadiazol-2-amine profile

5-Methyl-1,3,4-thiadiazol-2-amine is a heterocyclic compound that has been investigated for its potential biological activities. It is known to exhibit antimicrobial, anti-inflammatory, and analgesic properties. Research has explored its synthesis through various methods, including the reaction of 2-amino-5-methylthiazole with hydrazine hydrate. Studies have focused on understanding its mechanism of action, particularly its ability to inhibit the growth of certain bacteria and fungi. Its potential as a lead compound for the development of new drugs is being explored, prompting continued research into its pharmacological properties.'
```

ID Source	ID
PubMed CID	66949
CHEMBL ID	1288960
CHEBI ID	194873
SCHEMBL ID	282505
SCHEMBL ID	21228555

Synonym
BB 0217150
108-33-8
2-amino-5-methylthiadiazole
nsc-137228
wln: t5nn dsj c1 e1
usaf cy-3
1,4-thiadiazole, 2-amino-5-methyl-
2-amino-5-methyl-1,4-thiadiazole
1,4-thiadiazol-2-amine, 5-methyl-
nsc137228
nsc-526661
nsc526661
5-methyl-1,3,4-thiadiazol-2-amine
amino-5-methyl-1,3,4-thiadiazole
MLS001049227
5-methyl-[1,3,4]thiadiazol-2-ylamine
smr000427775
nsc 137228
matd
2-amino-5-methyl-1,3,4-thiadiazole
1,3,4-thiadiazole, 2-amino-5-methyl-
1,3,4-thiadiazol-2-amine, 5-methyl-
einecs 203-573-7
2-methyl-5-amino-1,3,4-thiadiazole
5-methyl-1,3,4-thiadiazole-2-amine
5-methyl-1,3,4-thiadiazol-2-ylamine
ai3-61163
STK016821
A0874
inchi=1/c3h5n3s/c1-2-5-6-3(4)7-2/h1h3,(h2,4,6)
hmpuhxcguhdvbi-uhfffaoysa-
AKOS000100063
CHEBI:194873
NCGC00246452-01
nc799929em ,
unii-nc799929em
CHEMBL1288960 ,
bdbm50331847
5-amino-2-methyl-1,3,4-thiadiazole
HMS2787M24
PS-4597
FT-0620585
SCHEMBL282505
5-methyl-2 -amino-1,3,4-thiadiazole
5-methyl-2-amino-1,3,4-thiadiazole
2-amino-5- methyl-1,3,4-thiadiazole
amino-5-methyl 1,3,4-thiadiazole
5-methyl-2-amino-1,3,4 -thiadiazole
W-108723
DTXSID70148347
F1423-2916
2-amino-5-methyl-1,3,4-thiadiazole, 97%
mfcd00003110
Z56900928
SY004265
SCHEMBL21228555
AMY3777
CS-0076370
F13849
EN300-17271

Class	Description
thiadiazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Luciferase	Photinus pyralis (common eastern firefly)	Potency	0.0239	0.0072	15.7588	89.3584	AID588342
geminin	Homo sapiens (human)	Potency	29.0929	0.0046	11.3741	33.4983	AID624296
Guanine nucleotide-binding protein G	Homo sapiens (human)	Potency	10.0000	1.9953	25.5327	50.1187	AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of inflammatory response to antigenic stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
renal water homeostasis	Guanine nucleotide-binding protein G	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Guanine nucleotide-binding protein G	Homo sapiens (human)
regulation of insulin secretion	Guanine nucleotide-binding protein G	Homo sapiens (human)
cellular response to glucagon stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
G protein activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
adenylate cyclase activator activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Guanine nucleotide-binding protein G	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (37)

Assay ID	Title	Year	Journal	Article
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID756686	Activation of AMPKalpha in rat L6 cells assessed as phosphorylation at Thr172 after 40 mins to 24 hrs by Western blot analysis	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and mechanism of hypoglycemic activity of benzothiazole derivatives.
AID1852929	Redox activity of compound assessed as redox index at 1 uM measured by resazurin assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID554332	Inhibition of Leishmania major PTR1 at 5 uM	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase.
AID1852923	Aqueous stability of the compound at pH 7.4 measured after 60 mins by spectrophotometric analysis	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1852916	Inhibition of recombinant Escherichia coli MurA assessed as residual activity at 500 uM using UDP-N-acetylglucosamine as substrate and measured by malachite green based colorimetric assay relative to control	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID554331	Lipophilicity, log D of the compound in octanol buffer at pH 7.4	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase.
AID1852917	Inhibition of recombinant Escherichia coli MurA assessed as residual activity at 500 uM using UDP-N-acetylglucosamine as substrate preincubated for 30 mins in presence of 1 mM DTT followed by substrate addition and measured by malachite green based colori	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID756681	Activation of AMPK in rat L6 cells assessed as increase of [3H]dGlc uptake at 100 uM after 5 hrs in presence of insulin	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and mechanism of hypoglycemic activity of benzothiazole derivatives.
AID1852922	Inhibition of recombinant Escherichia coli DdlB assessed as residual activity at 500 uM using D-alanine as substrate incubated for 20 mins and measured by malachite green based colorimetric assay relative to control	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1852928	Redox activity of compound assessed as redox index at 10 uM measured by resazurin assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1852927	Redox activity of compound assessed as redox index at 100 uM in presence of 100 uM TCEP measured by H2DCFDA assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1852930	Thiol reactivity of compound at 100 uM measured by DTNB assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1852920	Inhibition of recombinant SARS-CoV-2 3CLpro expressed in Escherichia coli NiCo21(DE3) assessed as residual activity at 500 uM using DABCYL-KTSAVLQSGFRKME-EDANS as substrate preincubated for 30 mins in presence of 1mM DTT followed by substrate addition and	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID554330	Solubility of the compound at pH 7.4	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase.
AID539004	Inhibition of Aspergillus fumigatus ChiA1 expressed in Pichia pastoris at 1 mM after 70 mins	2010	Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23	Acetazolamide-based fungal chitinase inhibitors.
AID1852926	Redox activity of compound assessed as redox index at 100 uM measured by H2DCFDA assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1852915	Inhibition of recombinant Escherichia coli MurA assessed as residual activity at 500 uM using UDP-N-acetylglucosamine as substrate preincubated for 30 mins followed by substrate addition and measured by malachite green based colorimetric assay relative to	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID756690	Activation of AMPK in rat L6 cells assessed as increase of [3H]dGlc uptake at 100 uM after 5 hrs relative to control	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and mechanism of hypoglycemic activity of benzothiazole derivatives.
AID1852921	Inhibition of Mycobacterium tuberculosis MetAP1a assessed as residual activity at 625 uM using L-methionine 7-amido-4-methylcoumarin as fluorogenic substrate and measured by fluorescence based assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1852919	Inhibition of recombinant SARS-CoV-2 3CLpro expressed in Escherichia coli NiCo21(DE3) assessed as residual activity at 500 uM using DABCYL-KTSAVLQSGFRKME-EDANS as substrate preincubated for 30 mins followed by substrate addition and measured by FRET assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1852931	Thiol reactivity of compound measured by TNB2- assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1852924	Redox activity of compound assessed as redox index at 100 uM measured by HRP-PR assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID539002	Inhibition of Aspergillus fumigatus ChiA1 expressed in Pichia pastoris after 70 mins	2010	Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23	Acetazolamide-based fungal chitinase inhibitors.
AID1852925	Redox activity of compound assessed as redox index at 100 uM in presence of 1 mM DTT measured by HRP-PR assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (11.11)	29.6817
2010's	6 (66.67)	24.3611
2020's	2 (22.22)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
2,4-dinitrophenol 2,4-Dinitrophenol: A toxic dye, chemically related to trinitrophenol (picric acid), used in biochemical studies of oxidative processes where it uncouples oxidative phosphorylation. It is also used as a metabolic stimulant. (Stedman, 26th ed). dinitrophenol : Members of the class of nitrophenol carrying two nitro substituents.. 2,4-dinitrophenol : A dinitrophenol having the nitro groups at the 2- and 4-positions.	2.08	1	dinitrophenol	allergen; antiseptic drug; bacterial xenobiotic metabolite; geroprotector; oxidative phosphorylation inhibitor
4-aminopyridine [no description available]	2.06	1	aminopyridine; aromatic amine	avicide; orphan drug; potassium channel blocker
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	2.05	1	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
2-aminothiazole 2-aminothiazole: RN given refers to parent cpd; structure. 1,3-thiazol-2-amine : A primary amino compound that is 1,3-thiazole substituted by an amino group at position 2.	2.57	2	1,3-thiazoles; primary amino compound
kinetin Kinetin: A furanyl adenine found in PLANTS and FUNGI. It has plant growth regulation effects.. cytokinin : A phytohormone that promote cell division, or cytokinesis, in plant roots and shoots.. kinetin : A member of the class of 6-aminopurines that is adenine carrying a (furan-2-ylmethyl) substituent at the exocyclic amino group.	2.05	1	6-aminopurines; furans	cytokinin; geroprotector
pyrimethamine Maloprim: contains above 2 cpds	2.06	1	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.	2.06	1	benzothiazoles
sulfathiazole Sulfathiazole: A sulfathiazole compound that is used as a short-acting anti-infective agent. It is no longer commonly used systemically due to its toxicity, but may still be applied topically in combination with other drugs for the treatment of vaginal and skin infections, and is still used in veterinary medicine.. sulfathiazole : A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position.	2.41	1	1,3-thiazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
benzotriazole benzotriazole: inhibitor of atmospheric metal corrosion; also component of motion picture film & Neva brake fluid. benzotriazole : The simplest member of the class of benzotriazoles that consists of a benzene nucleus fused to a 1H-1,2,3-triazole ring.	2.08	1	benzotriazoles	environmental contaminant; xenobiotic
benzothiazole benzothiazole: structure. benzothiazole : An organic heterobicyclic compound that is a fusion product between benzene and thiazole. The parent of the class of benzothiazoles.	2.08	1	benzothiazoles	environmental contaminant; plant metabolite; xenobiotic
2-amino-5-nitrothiazole 2-amino-5-nitrothiazole: RN given refers to cpd without isomeric designation	2.08	1	C-nitro compound; thiazoles
2-aminobenzothiazole [no description available]	2.48	2	benzothiazoles
phthalazine phthalazine : An azaarene that is the 2,3-diaza analogue of naphthalene. The parent of the class of phthalazines.	2.06	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; phthalazines
indole-3-carbaldehyde indole-3-carbaldehyde: metabolite of tryptophan; structure. indole-3-carbaldehyde : A heteroarenecarbaldehyde that is indole in which the hydrogen at position 3 has been replaced by a formyl group.	2.06	1	heteroarenecarbaldehyde; indole alkaloid; indoles	bacterial metabolite; human xenobiotic metabolite; marine metabolite; plant metabolite
8-chlorotheophylline [no description available]	2.05	1	organochlorine compound; purines	central nervous system stimulant
2-amino-1,3,4-thiadiazole 2-amino-1,3,4-thiadiazole: structure; RN given refers to parent cpd	2.48	2
4-aminoquinoline [no description available]	2.06	1
2-(4-aminophenyl)ethylamine 2-(4-aminophenyl)ethylamine: used to prepare derivatives of reducing oligosaccharides; structure given in first source	2.06	1
4-amino-2-methylquinoline 4-amino-2-methylquinoline: used to induce miniature endplate potentials	2.06	1
5-amino-1,3,4-thiadiazole-2-sulfonamide 5-amino-1,3,4-thiadiazole-2-sulfonamide: structure in first source	2.05	1
allosamidin allosamidin: Anti-Asthmatic	2.05	1
2-amino-5-phenyl-1,3,4-thiadiazole 2-amino-5-phenyl-1,3,4-thiadiazole: structure in first source	2.06	1
2-amino-5-methylthiazole 2-amino-5-methylthiazole: binds the W191G cavity of E coli cytochrome c peroxidase	2.41	1
5-(2-phenylethyl)-1,3,4-thiadiazol-2-amine [no description available]	2.06	1	aromatic amine; thiadiazoles
methimazole Methimazole: A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.. methimazole : A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.	2.08	1	1,3-dihydroimidazole-2-thiones	antithyroid drug
pyrimidine-2-thiol pyrimidine-2-thiol: RN given refers to parent cpd. pyrimidine-2-thiol : Pyrimidine substituted at C-2 by a sulfanyl group.	2.08	1	aryl thiol; pyrimidines	allergen; corrosion inhibitor
2-mercaptothiazoline [no description available]	2.08	1

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	2.08	1
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	2.08	1

5-Methyl-1,3,4-thiadiazol-2-amine

Cross-References

Synonyms (60)

Drug Classes (1)

Protein Targets (4)

Potency Measurements

Inhibition Measurements

Biological Processes (5)

Molecular Functions (2)

Ceullar Components (1)

Bioassays (37)

Research

Studies (9)

Market Indicators

Research Demand Index: 12.22

Study Types

5-Methyl-1,3,4-thiadiazol-2-amine

Cross-References

Synonyms (60)

Drug Classes (1)

Protein Targets (4)

Potency Measurements

Inhibition Measurements

Biological Processes (5)

Molecular Functions (2)

Ceullar Components (1)

Bioassays (37)

Research

Studies (9)

Market Indicators

Research Demand Index: 12.22

Study Types

Related Drugs (27)

Related Conditions (4)